Charles Boguslaski has more than 15 years of investment banking and financial restructuring experience. He has been recognized by various industry authorities for his execution of complex, creative solutions for his clients.
Mr. Boguslaski has represented both public and private companies, boards of directors, creditor groups, and investors on mergers and acquisitions, capital raises, and financial restructuring engagements, including Section 363 Sales and internal reorganizations. He also has provided valuations, fairness opinions, and testified as an expert witness in bankruptcy court. These assignments span a number of industries, including consumer products, business services, transportation, healthcare, hospitality, retail, professional services, manufacturing, telecommunications, and automotive. His representative engagements include Monitor Co. Group, Exide Technologies, DirectBuy Holdings, Enron Corp., Linens ‘n Things, Chicago Sun-Times, United Airlines Corp., and American Airlines.
Prior to joining Carl Marks, Mr. Boguslaski worked for Gordian Group, LLC, a middle-market investment banking firm focused on financial restructurings and distressed M&A transactions. Previously, he served in the corporate development group for Bayer Biological Products as it was sold to Cerberus. He began his career at LECG, a premier micro-economic consulting firm, where he advised on a variety of engagements, including mergers, financial valuations and business analyses, bankruptcies, financial damages, and labor disputes.
Mr. Boguslaski graduated magna cum laude from Boston College with a BS in Finance and Economics and received an MBA with a concentration in Finance from the Yale School of Management. He is a board member of Serim Research, a dry reagent technology diagnostic company. He is registered with FINRA as a General Securities Representative.